Yuki Ichimura

Yuki Ichimura

Auto-generated profile, based on publicly available information

Yuki Ichimura

Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
RTRyota Tanaka
Ryota Tanaka
YIYuki Ichimura
Yuki Ichimura
NKNoriko Kubota
Noriko Kubota
ASAkimasa Saito
Akimasa Saito
YNYoshiyuki Nakamura
Yoshiyuki Nakamura
NONaoko Okiyama
Naoko Okiyama

8 April 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YIYuki Ichimura
Yuki Ichimura
RKRisa Konishi
Risa Konishi
MSMiwako Shobo
Miwako Shobo
RTRyota Tanaka
Ryota Tanaka
NKNoriko Kubota
Noriko Kubota
NONaoko Okiyama
Naoko Okiyama
Anti-melanoma differentiation–associated gene 5 (MDA5) antibody–positive dermatomyositis (DM) is characterized by amyopathic DM with interstitial lung disease (ILD). Patients with anti-MDA5 antibody–associated ILD frequently develop rapidly progression and present high mortality rate in the acute phase. Here, we established a murine model of ILD mediated by autoimmunity against MDA5. Mice immunized with recombinant murine MDA5 whole protein, accompanied with complete Freund’s adjuvant once a week for four times, developed MDA5-reactive T cells and anti-MDA5 antibodies. After acute lung injury induced by intranasal administration of polyinosinic-polycytidylic acid [poly (I:C)] mimicking viral infection, the MDA5-immunized mice developed fibrotic ILD representing prolonged respiratory inflammation accompanied by fibrotic changes 2 wk after poly (I:C)-administration, while the control mice had quickly and completely recovered from the respiratory inflammation. Treatment with anti-CD4 depleting antibody, but not anti-CD8 depleting antibody, suppressed the severity of MDA5-induced fibrotic ILD. Upregulation of interleukin (IL)-6 mRNA, which was temporarily observed in poly (I:C)-treated mice, was prolonged in MDA5-immunized mice. Treatment with anti-IL-6 receptor antibody ameliorated the MDA5-induced fibrotic ILD. These results suggested that autoimmunity against MDA5 exacerbates toll-like receptor 3-mediated acute lung injury, and prolongs inflammation resulting in the development of fibrotic ILD. IL-6 may play a key role initiating ILD in this model.

6 July 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
RTRyota Tanaka
Ryota Tanaka
YIYuki Ichimura
Yuki Ichimura
NKNoriko Kubota
Noriko Kubota
RKRisa Konishi
Risa Konishi
YNYoshiyuki Nakamura
Yoshiyuki Nakamura
NONaoko Okiyama
Naoko Okiyama

1 June 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
ASAkimasa Saito
Akimasa Saito
YIYuki Ichimura
Yuki Ichimura
NKNoriko Kubota
Noriko Kubota
RTRyota Tanaka
Ryota Tanaka
YNYoshiyuki Nakamura
Yoshiyuki Nakamura
NONaoko Okiyama
Naoko Okiyama

5 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KOKauzmasa Oya
Kauzmasa Oya
YNYoshiyuki Nakamura
Yoshiyuki Nakamura
ZZZHU ZHENJIE
ZHU ZHENJIE
RTRyota Tanaka
Ryota Tanaka
NONaoko Okiyama
Naoko Okiyama
YFYasuhiro Fujisawa
Yasuhiro Fujisawa
The exact mechanisms of the imiquimod (IMQ)-induced antitumor effect have not been fully understood. Although both topical IMQ treatment and anti-PD-1 antibody may be used for primary skin lesions or skin metastases of various cancers, the efficacy of each monotherapy for these lesions is insufficient. Using a murine tumor model and human samples, we aimed to elucidate the detailed mechanisms of the IMQ-induced antitumor effect and analyzed the antitumor effect of combination therapy of topical IMQ plus anti-PD-1 antibody. Topical IMQ significantly suppressed the tumor growth of MC38 in wildtype mice. IMQ upregulated interferon γ (IFN-γ) expression in CD8+ T cells in both the lymph nodes and the tumor, and the antitumor effect was abolished in both Rag1-deficient mice and IFN-γ-deficient mice, indicating that IFN-γ produced by CD8+ T cells play a crucial role in the IMQ-induced antitumor effect. IMQ also upregulated PD-1 expression in T cells as well as PD-L1/PD-L2 expression in myeloid cells, suggesting that IMQ induces not only T-cell activation but also T-cell exhaustion by enhanced PD-1 inhibitory signaling. Combination therapy of topical IMQ plus anti-PD-1 antibody exerted a significantly potent antitumor effect when compared with each single therapy, indicating that the combination therapy is a promising therapy for the skin lesions of various cancers.

25 October 2022 in Immunological Medicine
Verified
Journal Article
Open access
RKRisa Konishi
Risa Konishi
YIYuki Ichimura
Yuki Ichimura
NONaoko Okiyama
Naoko Okiyama
Idiopathic inflammatory myopathies (IIMs) are characterized by inflammation of muscles and other organs. Several myositis-specific autoantibodies (MSAs) have been identified in IIMs and were found to be associated with distinct clinical features. Although MSAs are valuable for the diagnosis of IIMs, the pathogenic roles of these antibodies remain unknown. To investigate the pathogenesis of IIMs, several animal models of experimental myositis have been established. Classical murine models of autoimmune myositis, experimental autoimmune myositis, and C protein-induced myositis are established by immunization with muscle-specific antigens, myosin, and skeletal C protein, respectively. Furthermore, a murine model of experimental myositis was generated by immunization with a murine recombinant histidyl-tRNA synthetase, Jo-1, in which muscle and lung inflammation reflecting anti-synthetase syndrome are induced depending on acquired immunity. Recently, the transfer of human IgGs from patients with immune-mediated necrotizing myopathy, comprising anti-signal recognition particles and anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibodies, was found to induce complement-mediated myositis in recipient mice. CD8+ T cell-mediated myositis can be established depending on autoimmunity against transcriptional intermediary factor 1γ (TIF1γ), an autoantigen for MSAs induced by recombinant human TIF1γ immunization. These new murine models reflecting MSA-related IIMs are useful tools for accurately understanding the pathological mechanisms underlying IIMs.